行情

IMDZ

IMDZ

Immune Design
NASDAQ

实时行情|Nasdaq Last Sale

5.85
0.00
0.00%
已退市 09:30 10/15 EDT
开盘
--
昨收
5.85
最高
--
最低
--
成交量
--
成交额
--
52周最高
5.85
52周最低
1.100
市值
2.83亿
市盈率(TTM)
-5.1433
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

IMDZ 新闻

  • 德国警告英国脱欧将推迟 协议不足以解决技术性问题
  • 新浪美股.2小时前
  • 美联储5400亿美元"扩表" 分析师警告:市场可能吃不消
  • 新浪美股.2小时前
  • 投行"黑马"业务突起 银行业RMBS交易半年获利10亿
  • 新浪美股.3小时前
  • 美银美林:投资者无视市场高涨 仍偏爱防御性资产
  • 新浪美股.4小时前

更多

所属板块

生物技术和医学研究
+2.02%
制药与医学研究
+1.31%

热门股票

名称
价格
涨跌幅

IMDZ 简况

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. The Company has engineered its technologies to activate the immune system's natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer. The Company is engaged in developing multiple product candidates from its two discovery platforms, ZVex and GLAAS. Its primary product candidates, CMB305 and G100, utilize multiple immuno-oncology approaches and are in multiple Phase I and Phase II trials. CMB305 is targeting the NY-ESO-1 tumor antigen, in which a priming agent called LV305 from its ZVex platform is dosed sequentially with an agent from its GLAAS platform. G100 leverages the range of endogenous antigens found in the tumor microenvironment, including neoantigens.
展开

Webull提供Immune Design Corp的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。